| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/25/2013 | WO2013059351A1 Stabilizers for hemostatic products |
| 04/25/2013 | WO2013059295A2 Polymeric depots for localization of an agent to biological sites |
| 04/25/2013 | WO2013058996A1 Two phase pharmaceutical delivery system |
| 04/25/2013 | WO2013058812A1 Targeted delivery to pancreatic islet endothelial cells |
| 04/25/2013 | WO2013058751A1 Cellulose derivatives for enhancing bioavailability of flavonoids |
| 04/25/2013 | WO2013058496A1 Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof |
| 04/25/2013 | WO2013058450A1 Stabilized eperisone medical composition, and sustained-release preparation containing same |
| 04/25/2013 | WO2013058411A1 Solution for oral administration |
| 04/25/2013 | WO2013058303A1 Medicinal composition |
| 04/25/2013 | WO2013058302A1 Water-soluble soybean polysaccharides and manufacturing process therefor |
| 04/25/2013 | WO2013058080A1 Oily gel composition |
| 04/25/2013 | WO2013057747A1 Anti-tumoral compound and relative production process |
| 04/25/2013 | WO2013057570A2 Acrylic polymer formulations |
| 04/25/2013 | WO2013057461A1 Paste comprising non-steroidal anti-inflammatory |
| 04/25/2013 | WO2013057455A2 Cosmetic or dermatological composition comprising alkyl polypentoside vesicles, and method for preparing same |
| 04/25/2013 | WO2013057208A1 Compositions and methods for reducing the proliferation and viability of microbial agents |
| 04/25/2013 | WO2013057171A1 Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii |
| 04/25/2013 | WO2013057169A1 Pharmaceutical nanosuspension |
| 04/25/2013 | WO2013057167A1 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| 04/25/2013 | WO2013056994A1 Improvements in or relating to organic compounds |
| 04/25/2013 | WO2013056993A1 Improvements in or relating to organic compounds |
| 04/25/2013 | WO2013056709A1 Nicotine chewing gum with improved utilization of nicotine |
| 04/25/2013 | WO2013056453A1 Preparation method and application of injection for needleless injection |
| 04/25/2013 | WO2013033438A3 Nanoparticle peg modification with h-phosphonates |
| 04/25/2013 | WO2013032643A3 Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| 04/25/2013 | WO2013025545A3 Drug delivery systems and method of reducing foal infection by treating mares with gallium salts |
| 04/25/2013 | WO2013019658A3 Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| 04/25/2013 | WO2013016544A3 Templated islet cells and small islet cell clusters for diabetes treatment |
| 04/25/2013 | WO2013013038A3 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 04/25/2013 | WO2012173933A3 Activatable nanoprobes for intracellular drug delivery |
| 04/25/2013 | WO2012162629A3 Popcorn shape gold nanoparticle for targeted diagnosis, photothermal treatment and in-situ monitoring therapy response for cancer and multiple drug resistance bacteria |
| 04/25/2013 | WO2012145470A3 Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| 04/25/2013 | US20130103157 Polymeric adhesive for anchoring compliant materials to another surface |
| 04/25/2013 | US20130102760 Immunoglobulin Preparations Having Increased Stability |
| 04/25/2013 | US20130102691 Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution |
| 04/25/2013 | US20130102690 Collagen-polysaccharide materials mimicking blood vessels, tissues and bones for medical, pharmaceutical and orthopedic applications, and processes for producing the same |
| 04/25/2013 | US20130102688 Oil-in-water emulsion composition and method for producing same |
| 04/25/2013 | US20130102684 Bioactive compositions |
| 04/25/2013 | US20130102675 Solid Pharmaceutical Compositions Containing Pregabalin |
| 04/25/2013 | US20130102663 Nutritional composition |
| 04/25/2013 | US20130102657 Anti-angiogenic compositions and methods of use |
| 04/25/2013 | US20130102634 Stabilized and Preserved Ketotifen Ophthalmic Compositions |
| 04/25/2013 | US20130102588 Tolvaptan solid dispersion and its preparation method |
| 04/25/2013 | US20130102545 Temperature dependent activation of catalytic nucleic acids for controlled active substance release |
| 04/25/2013 | US20130102521 Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| 04/25/2013 | US20130102471 Formula composition as delivery system used in pharmaceutical and pesticide applications |
| 04/25/2013 | US20130101661 Compositions for treating biofilms and methods for using same |
| 04/25/2013 | US20130101656 In situ gelling drug delivery system |
| 04/25/2013 | US20130101647 Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved |
| 04/25/2013 | US20130101639 Bone semi-permeable device |
| 04/25/2013 | US20130101638 Bone semi-permeable device |
| 04/25/2013 | US20130101637 Bone Semi-Permeable Device |
| 04/25/2013 | US20130101633 Antimicrobial gels |
| 04/25/2013 | US20130101608 Human antibody drug conjugates against tissue factor |
| 04/25/2013 | US20130101607 Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) Single Chain FV Antibody Fragment Conjugates and Methods of Use Thereof |
| 04/25/2013 | US20130101593 Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| 04/25/2013 | US20130101546 Protein-Polymer-Drug Conjugates |
| 04/25/2013 | US20130101529 Composition for treating and/or preventing periodontal disease |
| 04/25/2013 | US20130101527 Methods, compounds and pharmaceutical compositions for treating neurological disorders |
| 04/25/2013 | US20130101516 Nanoparticles and nanoparticle compositions |
| 04/25/2013 | US20130101510 Methods of treating parkinson's disease using viral vectors |
| 04/25/2013 | US20130101508 Stabilization of radiopharmaceutical compositions using ascorbic acid |
| 04/25/2013 | US20130098286 Method and agent for detecting drugs in beverages |
| 04/25/2013 | CA2853084A1 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| 04/25/2013 | CA2852917A1 Amine cationic lipids and uses thereof |
| 04/25/2013 | CA2852874A1 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| 04/25/2013 | CA2852848A1 Acrylic polymer formulations |
| 04/25/2013 | CA2852788A1 Nicotine chewing gum with improved utilization of nicotine |
| 04/25/2013 | CA2852618A1 Pharmaceutical composition |
| 04/25/2013 | CA2852613A1 Paste comprising non-steroidal anti-inflammatory |
| 04/25/2013 | CA2852447A1 Two phase pharmaceutical delivery system |
| 04/25/2013 | CA2852397A1 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| 04/25/2013 | CA2852380A1 Compounds, compositions, and methods for reducing or eliminating bitter taste |
| 04/25/2013 | CA2852347A1 Pharmaceutical nanosuspension |
| 04/25/2013 | CA2851999A1 Solution for oral administration |
| 04/25/2013 | CA2851651A1 Etanercept formulations stabilized with xylitol |
| 04/25/2013 | CA2851646A1 Etanercept formulations stabilized with meglumine |
| 04/25/2013 | CA2851642A1 Etanercept formulations stabilized with sodium chloride |
| 04/25/2013 | CA2851639A1 Etanercept formulations stabilized with metal ions |
| 04/25/2013 | CA2851635A1 Etanercept formulations stabilized with amino acids |
| 04/25/2013 | CA2851628A1 Etanercept formulations stabilized with combinations of sugars and polyols |
| 04/25/2013 | CA2851425A1 Anti-tumoral compound and relative production process |
| 04/25/2013 | CA2851057A1 Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii |
| 04/24/2013 | EP2583940A1 Stabilization of carbon nanomaterials and hydrophobic compounds by copolymers |
| 04/24/2013 | EP2583691A1 Agent for treating renal fibrosis |
| 04/24/2013 | EP2583690A1 Liposome including elastin-like polypeptide hydrophobic group conjugate, chemosensitizer and anticancer agent and use thereof |
| 04/24/2013 | EP2583689A1 Liposome including elastin-like polypeptides and use thereof |
| 04/24/2013 | EP2583674A2 Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day |
| 04/24/2013 | EP2583671A1 Colloidal nanoscale carriers for active hydrophilic substances and method for producing same |
| 04/24/2013 | EP2583669A1 Taste-masked orally disintegrating tablets of memantine hydrochloride |
| 04/24/2013 | EP2583668A1 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| 04/24/2013 | EP2583662A1 Composition comprising a meroterpen to manage oily skin with tendency to develop acne |
| 04/24/2013 | EP2582741A2 Boronated polymers |
| 04/24/2013 | EP2582734A1 Novel thickening polymers for oil phases |
| 04/24/2013 | EP2582728A2 Human antibody drug conjugates against tissue factor |
| 04/24/2013 | EP2582672A1 X-ray and gamma-photon activable organic compounds, their preparation and their uses |
| 04/24/2013 | EP2582400A2 Tuned multifunctional magnetic nanoparticles for biomedicine |
| 04/24/2013 | EP2582396A2 Long lasting drug formulations |
| 04/24/2013 | EP2582395A2 Methods for the preparation of injectable depot compositions |
| 04/24/2013 | EP2582394A1 Stabilised human immunoglobulin composition |